Spots Global Cancer Trial Database for mm
Every month we try and update this database with for mm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | NCT03850704 | Multiple Myelom... | Selinexor | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | NCT00689000 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | NCT03106428 | Acute Myeloid L... Multiple Myelom... Diffuse Large B... | MEDI7247 | 18 Years - 100 Years | MedImmune LLC | |
| Connect® MM- The Multiple Myeloma Disease Registry | NCT01081028 | Multiple Myelom... | 18 Years - | Celgene | ||
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | NCT00038818 | Chronic Myeloge... Multiple Myelom... Non Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | CD8 Depleted Do... | - | M.D. Anderson Cancer Center | |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | NCT00499239 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | GS-9219 | 18 Years - | Gilead Sciences | |
| Bortezomib Consolidation Trial | NCT01517724 | Multiple Myelom... | Bortezomib | 18 Years - 70 Years | University College, London | |
| Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | NCT02719015 | Melanoma | rAd.CD40L Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | NCT01413178 | Myeloma | Busulfan Melphalan Questionnaire G-CSF High Dose Melph... Stem cell trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma | NCT00804908 | Melanoma Metastatic Mela... Skin Cancer | temozolomide ABT-888 Placebo | 18 Years - | AbbVie | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro | NCT01472627 | Multiple Myelom... | Blood draws | 18 Years - | Dana-Farber Cancer Institute | |
| Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | NCT02114502 | Myeloma | Carfilzomib SAHA Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin Dexamethasone Caphosol Glutamine Pyridoxine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | NCT04136756 | Multiple Myelom... Non-Hodgkin Lym... Indolent Non-Ho... | NKTR-255 NKTR-255 Q21 Rituximab Daratumumab | 18 Years - 80 Years | Nektar Therapeutics | |
| Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | NCT00710528 | Chronic Lymphoc... Lymphoma, Non-H... Acute Myeloid L... Multiple Myelom... | CAL-101 | 18 Years - | Gilead Sciences | |
| Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma | NCT00998270 | Multiple Myelom... | Autologous bone... Allogeneic bone... | 18 Years - 55 Years | Tehran University of Medical Sciences | |
| Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma | NCT00998270 | Multiple Myelom... | Autologous bone... Allogeneic bone... | 18 Years - 55 Years | Tehran University of Medical Sciences | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma | NCT01793051 | Myeloma | Minocycline Placebo Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | NCT00446342 | B-lymphoid Mali... Chronic Lymphoc... Mantle Cell Lym... Multiple Myelom... | SNS-032 Injecti... | 18 Years - | Sunesis Pharmaceuticals | |
| Radiation and Combination Immunotherapy for Melanoma | NCT03850691 | Metastatic Mela... | Aldesleukin: Al... Nivolumab: Coho... Nivolumab: Coho... Ipilimumab: Coh... | 18 Years - 80 Years | Masonic Cancer Center, University of Minnesota | |
| Two Cycles of PAD Combination by AHCT in MM | NCT01370434 | Multiple Myelom... | PAD combination | 15 Years - 65 Years | Cooperative Study Group A for Hematology | |
| The clonoSEQ® Watch Registry | NCT04545333 | Acute Lymphobla... Chronic Lymphoc... Multiple Myelom... Non-hodgkin Lym... | clonoSEQ Assay | 18 Years - | Adaptive Biotechnologies | |
| Bortezomib Consolidation Trial | NCT01517724 | Multiple Myelom... | Bortezomib | 18 Years - 70 Years | University College, London | |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | NCT00446342 | B-lymphoid Mali... Chronic Lymphoc... Mantle Cell Lym... Multiple Myelom... | SNS-032 Injecti... | 18 Years - | Sunesis Pharmaceuticals | |
| Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML | NCT04887259 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... | LAVA-051 Interleukin 2 | 18 Years - | Lava Therapeutics | |
| Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | NCT01927718 | Myeloma | Thalidomide Lenalidomide Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | NCT00499239 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | GS-9219 | 18 Years - | Gilead Sciences | |
| Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients | NCT01269203 | Multiple Myelom... | Curcumin Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer | NCT02240537 | Acute Myelogeno... Multiple Myelom... Myelodysplastic... Smoldering Mult... | Sargramostim BB-MPI-03 Montanide | 18 Years - | Benovus Bio, Inc. | |
| Connect® MM- The Multiple Myeloma Disease Registry | NCT01081028 | Multiple Myelom... | 18 Years - | Celgene | ||
| Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | NCT00916058 | Multiple Myelom... | Bendamustine Melphalan Bendamustine Bendamustine Bendamustine Bendamustine Bendamustine | 18 Years - | Weill Medical College of Cornell University | |
| Acupuncture for Chemo-Induced Peripheral Neuropathy | NCT00891618 | Lymphoma Myeloma Peripheral Neur... | Acupuncture | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | NCT00861510 | Lymphoma, Mantl... Leukemia, Lymph... Leukemia, Hairy... Waldenstrom Mac... Multiple Myelom... | ON01910 Na | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT01456689 | Multiple Myelom... | LGH447 midazolam | 18 Years - | Novartis | |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | NCT01531998 | Myeloma | Lenalidomide Bortezomib Siltuximab Dexamethasone Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma | NCT00065351 | Multiple Myelom... | CC-5013 | 18 Years - | Celgene | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine | NCT03762291 | Multiple Myelom... | CVD908ssb-TXSVN | 18 Years - | Baylor College of Medicine | |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | NCT03850704 | Multiple Myelom... | Selinexor | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT01456689 | Multiple Myelom... | LGH447 midazolam | 18 Years - | Novartis | |
| Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT | NCT05928156 | Multiple Myelom... Chronic Lymphoc... | Myeloma Coach o... Springboard Bey... | 18 Years - | Duke University | |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | NCT02223052 | Hematological N... Non-Hodgkin's L... Hodgkin's Lymph... Lymphoma Multiple Myelom... Acute Myeloid L... Leukemia Myelodysplastic... Neoplasms Melanoma Breast Cancer Metastatic Brea... Non-Small Cell ... Small Cell Lung... Renal Cell Carc... Glioblastoma Mu... Osteosarcoma Sarcoma Thyroid Cancer Genitourinary | CC-486 Vidaza | 18 Years - | Celgene | |
| Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | NCT01440582 | Myeloma | Panobinostat Bortezomib Lenalidomide Dexamethasone Symptom Questio... | 18 Years - | M.D. Anderson Cancer Center | |
| Multiple Myeloma Turkish Prospective Patient Registry | NCT04143932 | Multiple Myelom... Relapse Multipl... | 18 Years - | Turkish Hematology Association | ||
| Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies | NCT00460460 | Lymphoma | AZD4877 | 18 Years - | AstraZeneca | |
| Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | NCT00916058 | Multiple Myelom... | Bendamustine Melphalan Bendamustine Bendamustine Bendamustine Bendamustine Bendamustine | 18 Years - | Weill Medical College of Cornell University | |
| Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients | NCT01269203 | Multiple Myelom... | Curcumin Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | NCT00499239 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | GS-9219 | 18 Years - | Gilead Sciences | |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | NCT04150965 | Multiple Myelom... Relapsed Refrac... | Elotuzumab, pom... Anti-LAG-3 Anti-LAG-3 + Po... Anti-TIGIT Anti-TIGIT + Po... | 18 Years - | Multiple Myeloma Research Consortium | |
| The clonoSEQ® Watch Registry | NCT04545333 | Acute Lymphobla... Chronic Lymphoc... Multiple Myelom... Non-hodgkin Lym... | clonoSEQ Assay | 18 Years - | Adaptive Biotechnologies | |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma | NCT06435910 | Multiple Myelom... | DC vaccines | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | NCT04287660 | Multiple Myelom... | clarithromycin,... | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | NCT03850704 | Multiple Myelom... | Selinexor | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | NCT03850704 | Multiple Myelom... | Selinexor | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Inflammatory Cytokines in Symptom Production in Multiple Myeloma | NCT00688168 | Multiple Myelom... | Questionnaire Neurocognitive ... Neurosensory Te... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
